Health
Recce Pharmaceuticals” R327 demonstrates positive efficacy against ‘flesh-eating” bacteria – Proactive Investors Australia
RECCE® 327 (R327) has been shown to reduce deadly flesh-eating bacterial count below limit of quantification within 24 hours,…
RECCE® 327 (R327) has been shown to reduce deadly flesh-eating bacterial count below limit of quantification within 24 hours, at varying concentrations.Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q), a company developing new classes of synthetic anti-infectives,…
Continue Reading
-
Business23 hours agoWhy this fantastic blue chip ASX 200 share could rise 20%
-
General22 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
General15 hours agoPhotographers reveal iconic image of Gough Whitlam and Vincent Lingiari was posed on Wave Hill Walk-Off anniversary
-
Noosa News16 hours agoConcerns over WHO pandemic agreement